Big Pharma VCs jump in to back a $63M mission to tackle a genetic driver of Alzheimer’s
About five years ago a pair of scientists at the Gladstone Institutes — Robert Mahley and Yadong Huang — had seen enough clinical failures in Alzheimer’s drug research to urge a change in strategy. If the classic approach on leeching amyloid-beta out of the brain was producing only colossal failure, they said, why not zero in on a key genetic trigger linked to a well-defined risk of developing the disease?
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.